Reg. name: Idhifa®
Class: IDH2 inhibitor
Enasidenib is an oral, selective inhibitor of mutated Isocitrate Dehydrogenase 2 (IDH2). Enasidenib binds and inhibits the mutant IDH2 enzyme that is responsible for the accumulation of 2-Hydroxyglutarate (2-HG).
- Mondesir J, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives J Blood Med. 2016; 7: 171–180.
IDHIFA® is indicated for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with an Isocitrate Dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.